Overview

A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-ne

Status:
NOT_YET_RECRUITING

Trial end date:
2030-05-31

Target enrollment:

Participant gender:

Summary

This study is a randomised, open-label, multicentre phase III clinical study evaluating the efficacy and safety of JS105 combined with Dalpiciclib and Fulvestrant compared with Dalpiciclib and Fulvestrant in patients with PIK3CA-mutated, HR-positive, HER2-negative recurrent or metastatic breast cancer.

Phase:

PHASE3

Details

Lead Sponsor:

Risen (Suzhou) Pharma Tech Co., Ltd.

Treatments:

dalpiciclib
Fulvestrant